Makena

FDA approves drug to reduce risk of preterm birth

The U.S. Food and Drug Administration (FDA) has approved Makena (hydroxyprogesterone caproate) injection to reduce the risk of preterm delivery in pregnant women with a history of at…

Reader Survey

Please share your feedback! We’re interested to learn more about your experience with American Nurse Journal.

Survey

Take the 2024 Nursing Trends and Salary Survey, available now through November 1st 2024

See Past Results
cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Test Your Knowledge

What is the primary purpose of a 3-minute foot assessment in patients with comorbidities such as diabetes or peripheral arterial disease?